Imagenetix, Inc. (IAGX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerImagenetix, Inc. (IAGX) trades at $0.0002. Imagenetix, Inc. develops and markets natural-based nutritional supplements and over-the-counter topical creams, with a focus on its primary product, Celadrin, for joint health. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for IAGX: IAGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Imagenetix, Inc. (IAGX) Healthcare & Pipeline Overview
Imagenetix, Inc. is a healthcare company focused on developing, formulating, and marketing proprietary and natural-based nutritional supplements, primarily Celadrin for joint health. The company operates within the specialty and generic drug manufacturing sector, distributing products through diverse channels and licensing its intellectual property.
What Is the Investment Thesis for IAGX?
Imagenetix, Inc. presents a unique investment profile within the specialty and generic drug manufacturing sector. The company's focus on natural-based nutritional supplements and over-the-counter products, particularly Celadrin, caters to the growing demand for alternative healthcare solutions. With a market capitalization of $0.00 billion and a negative P/E ratio of -0.13, the company's financial performance indicates potential challenges. However, a gross margin of 41.6% suggests a viable product portfolio. Growth catalysts include expanding distribution channels and strategic licensing agreements. Potential risks involve the company's small size, limited financial resources, and the highly competitive nature of the healthcare industry. The company's beta of -406.06 suggests an inverse correlation with the market.
Based on FMP financials and quantitative analysis
IAGX Key Highlights
Gross Margin of 41.6% indicates potential profitability in product sales.
- Market Cap of $0.00B reflects the company's small size and limited market presence.
- Profit Margin of -2.6% suggests the company is currently operating at a loss.
- P/E Ratio of -0.13 indicates negative earnings, making valuation challenging.
- Beta of -406.06 suggests an inverse correlation with the market, potentially offering diversification benefits.
Who Are IAGX's Competitors?
IAGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IAGX's Key Strengths?
Proprietary product formulations (e.g., Celadrin).
- Established distribution network.
- Focus on natural-based products.
- Intellectual property licensing opportunities.
What Are IAGX's Weaknesses?
Small company size and limited resources.
- Negative profit margin.
- High beta value indicating volatility.
- Dependence on a limited product portfolio.
What Are the Key Risks for IAGX?
Financial-distress signal — its Altman Z-Score of -0.07 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-3.4%) — the business is not currently generating profit on shareholder capital.
- Limited financial resources may hinder growth initiatives.
- Intense competition in the healthcare industry.
- Regulatory changes affecting the supplement industry.
- Dependence on a limited product portfolio.
- Product liability claims.
What Are IAGX's Competitive Advantages?
- Proprietary product formulations.
- Established brand recognition for Celadrin.
- Multi-channel distribution network.
- Intellectual property licensing agreements.
What Does IAGX Do?
Founded in 1996 and based in San Diego, California, Imagenetix, Inc. operates within the healthcare sector, specifically in the realm of specialty and generic drug manufacturing. The company develops, formulates, and markets a range of proprietary and natural-based nutritional supplements, over-the-counter topical creams, and skincare products. Its flagship product, Celadrin, is a formulation designed to support joint health. In addition to its own product lines, Imagenetix, Inc. also generates revenue through licensing its intellectual property to third parties. The company employs a multi-channel distribution strategy, leveraging direct and mass marketing companies, nutritional and medical newsletters, and direct response radio and television to reach its target market. Imagenetix aims to provide consumers with natural alternatives for health and wellness, focusing on product efficacy and market accessibility. The company's size is relatively small, with only 5 employees, reflecting its focus on niche markets and specialized product offerings.
What Products and Services Does IAGX Offer?
- Develops proprietary nutritional supplements.
- Formulates natural-based health products.
- Markets over-the-counter topical creams.
- Specializes in skin care products.
- Offers Celadrin for joint health.
- Licenses intellectual property to third parties.
How Does IAGX Make Money?
- Develops and manufactures proprietary health products.
- Markets products through various distribution channels.
- Generates revenue through product sales.
- Licenses intellectual property for additional income.
What Industry Does IAGX Operate In?
Imagenetix, Inc. operates in the competitive specialty and generic drug manufacturing industry, which is characterized by increasing demand for over-the-counter and natural health products. Key competitors include both large pharmaceutical companies and smaller niche players. Imagenetix differentiates itself through its focus on proprietary formulations and natural ingredients, targeting consumers seeking alternative healthcare solutions. The company's success depends on its ability to innovate, effectively market its products, and navigate the complex regulatory landscape.
Who Are IAGX's Key Customers?
- Individuals seeking joint health solutions.
- Consumers interested in natural nutritional supplements.
- Customers of direct and mass marketing companies.
- Readers of nutritional and medical newsletters.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Imagenetix, Inc. stands at -3.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.2%, showing how much profit it generates from its asset base. A current ratio of 0.69 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Imagenetix, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Decky Goodrich. IAGX has traded publicly since 2000.
Financial Health
Imagenetix, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.07 places it in the distress zone, a signal of elevated financial risk.
IAGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IAGX Latest News
No recent news available for IAGX.
IAGX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IAGX.
Price Targets
Wall Street price target analysis for IAGX.
IAGX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IAGX; grades run from A+ (80-100) to F (below 30).
Leadership: Decky Goodrich
Managing Director
Decky Goodrich serves as the Managing Director of Imagenetix, Inc., overseeing the company's operations and strategic direction. With experience in managing small teams, Goodrich is responsible for guiding the company's development, formulation, and marketing of nutritional supplements and skincare products. His leadership is crucial in navigating the competitive healthcare market and driving the company's growth initiatives.
Track Record: Under Decky Goodrich's leadership, Imagenetix, Inc. has focused on maintaining its core product offerings, particularly Celadrin, and exploring licensing opportunities. The company has navigated the challenges of a competitive market while maintaining a focus on natural-based formulations. Goodrich's tenure has been marked by efforts to optimize distribution channels and manage the company's limited resources effectively.
IAGX OTC Market Information
The OTC Other tier, where Imagenetix trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of higher tiers like OTCQX or OTCQB. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. These companies are not required to adhere to the same stringent reporting standards as those listed on major exchanges like the NYSE or NASDAQ, leading to less transparency for investors.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of regular financial reporting increases the risk of investing in IAGX.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for Fraud or Manipulation: The OTC market is more susceptible to fraudulent activities and market manipulation.
- Lack of Regulatory Oversight: The absence of stringent regulatory oversight increases the risk of investing in IAGX.
- Going Concern Risk: Companies on the OTC Other tier may face going concern issues due to financial difficulties.
- Verify the company's legal status and registration.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal proceedings.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Years in Operation: Imagenetix has been in operation since 1996, indicating some level of business stability.
- Proprietary Product Formulations: The company has proprietary product formulations, such as Celadrin, which could indicate a competitive advantage.
- Multi-Channel Distribution Network: Imagenetix utilizes a multi-channel distribution network, which can enhance its market reach.
- Focus on Natural-Based Products: The company's focus on natural-based products aligns with growing consumer demand for alternative healthcare solutions.
Imagenetix, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for IAGX?
The main risks for Imagenetix, Inc. include its small size and limited financial resources, which may hinder its ability to compete effectively in the healthcare industry.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC status and lack of comprehensive reporting.